The North America Specialty Generics Market would witness market growth of 9.0% CAGR during the forecast period (2023-2030).
The complex or high-end specialty generics are generic equivalents of drugs. However, they follow different regulatory processes. The prevalence of many life-threatening diseases, such as cancer, Multiple Sclerosis (MS), and HIV, has increased regionally, which is expected to result in a rise in the need for specialized pharmaceuticals. For a variety of medication delivery methods, including intravenous, intradermal, intramuscular, intraperitoneal, subcutaneous, and others, specialty generic injectables are used to treat ailments ranging from cancer to autoimmune disorders.
During drug injection, a chemical is injected into the bloodstream using a hollow hypodermic needle. Oncology, autoimmune disorders, infectious diseases, and other indications are treated using specialty generics, which are sold through a variety of channels, including specialty pharmacies, retail pharmacies, and hospital pharmacies. Due to specific production needs, greater capital costs, and generally lower quantities as a result of a smaller patient population, specialized generics have a more competitive market than regular generics. This leads to better profits than standard generics and a lesser price drop relative to branded medicine. Since specialty generics are given by unique players, they typically require prior authorization in the market and special handling, administration, and monitoring.
The American Cancer Society reports that in 2018, there were roughly 154,050 lung cancer-related deaths in the United States, with an estimated 234,030 new cases of lung cancer being diagnosed. According to the American Lung Association, 541,000 Americans have received a lung cancer diagnosis at some time in their lives. The majority of patients have received a lung cancer diagnosis during the last five years. Each year, non-small cell lung cancer (NSCLC) is treated in tens of thousands of Americans. The market is expected to grow as a result of lung cancer's increasing prevalence. Because of the increase in cancer incidence, there is a greater need for products such as specialty generics, which boosts the regional market.
The US market dominated the North America Specialty Generics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $33,131.9 million by 2030. The Canada market is exhibiting a CAGR of 11.5% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 10.5% during (2023 - 2030).
Based on Type, the market is segmented into Injectables, Oral Drugs, and Others. Based on Application, the market is segmented into Inflammatory conditions, Multiple sclerosis, Hepatitis C, Oncology, and Others. Based on End Use, the market is segmented into Specialty Pharmacy, Retail Pharmacy, and Hospital Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Specialty Generics Market is Projected to reach USD 141.5 Billion by 2030, at a CAGR of 9.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Novartis AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Dr. Reddy’s Laboratories Ltd., Mallinckrodt PLC, Bausch Health Companies, Inc., Viatris, Inc. and Apotex, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Injectables
- Oral Drugs
- Others
By Application
- Inflammatory conditions
- Multiple sclerosis
- Hepatitis C
- Oncology
- Others
By End Use
- Specialty Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd.
- Fresenius SE & Co. KGaA
- Dr. Reddy’s Laboratories Ltd.
- Mallinckrodt PLC
- Bausch Health Companies, Inc.
- Viatris, Inc.
- Apotex, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Specialty Generics Market, by Type
1.4.2 North America Specialty Generics Market, by Application
1.4.3 North America Specialty Generics Market, by End Use
1.4.4 North America Specialty Generics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions: 2020, May – 2023, Jan) Leading Players
Chapter 4. North America Specialty Generics Market by Type
4.1 North America Injectables Market by Country
4.2 North America Oral Drugs Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Specialty Generics Market by Application
5.1 North America Inflammatory conditions Market by Country
5.2 North America Multiple sclerosis Market by Country
5.3 North America Hepatitis C Market by Country
5.4 North America Oncology Market by Country
5.5 North America Others Market by Country
Chapter 6. North America Specialty Generics Market by End Use
6.1 North America Specialty Pharmacy Market by Country
6.2 North America Retail Pharmacy Market by Country
6.3 North America Hospital Pharmacy Market by Country
Chapter 7. North America Specialty Generics Market by Country
7.1 US Specialty Generics Market
7.1.1 US Specialty Generics Market by Type
7.1.2 US Specialty Generics Market by Application
7.1.3 US Specialty Generics Market by End Use
7.2 Canada Specialty Generics Market
7.2.1 Canada Specialty Generics Market by Type
7.2.2 Canada Specialty Generics Market by Application
7.2.3 Canada Specialty Generics Market by End Use
7.3 Mexico Specialty Generics Market
7.3.1 Mexico Specialty Generics Market by Type
7.3.2 Mexico Specialty Generics Market by Application
7.3.3 Mexico Specialty Generics Market by End Use
7.4 Rest of North America Specialty Generics Market
7.4.1 Rest of North America Specialty Generics Market by Type
7.4.2 Rest of North America Specialty Generics Market by Application
7.4.3 Rest of North America Specialty Generics Market by End Use
Chapter 8. Company Profiles
8.1 Teva Pharmaceutical Industries Ltd.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 Hikma Pharmaceuticals PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Product Launches and Product Expansions:
8.4 Sun Pharmaceutical Industries Ltd.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.5 Fresenius SE & Co. KGaA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.6 Dr. Reddy’s Laboratories Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.7 Mallinckrodt PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.8 Bausch Health Companies, Inc
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Viatris, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.10. Apotex, Inc.
8.10.1 Company Overview
TABLE 1 North America Specialty Generics Market, 2019 - 2022, USD Million
TABLE 2 North America Specialty Generics Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Specialty Generics Market
TABLE 4 Product Launches And Product Expansions– Specialty Generics Market
TABLE 5 Acquisition and Mergers– Specialty Generics Market
TABLE 6 Approvals and Trials– Specialty Generics Market
TABLE 7 North America Specialty Generics Market by Type, 2019 - 2022, USD Million
TABLE 8 North America Specialty Generics Market by Type, 2023 - 2030, USD Million
TABLE 9 North America Injectables Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Injectables Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Oral Drugs Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Oral Drugs Market by Country, 2023 - 2030, USD Million
TABLE 13 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Specialty Generics Market by Application, 2019 - 2022, USD Million
TABLE 16 North America Specialty Generics Market by Application, 2023 - 2030, USD Million
TABLE 17 North America Inflammatory conditions Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Inflammatory conditions Market by Country, 2023 - 2030, USD Million
TABLE 19 North America Multiple sclerosis Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Multiple sclerosis Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Hepatitis C Market by Country, 2019 - 2022, USD Million
TABLE 22 North America Hepatitis C Market by Country, 2023 - 2030, USD Million
TABLE 23 North America Oncology Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Oncology Market by Country, 2023 - 2030, USD Million
TABLE 25 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 27 North America Specialty Generics Market by End Use, 2019 - 2022, USD Million
TABLE 28 North America Specialty Generics Market by End Use, 2023 - 2030, USD Million
TABLE 29 North America Specialty Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Specialty Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 31 North America Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 33 North America Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 35 North America Specialty Generics Market by Country, 2019 - 2022, USD Million
TABLE 36 North America Specialty Generics Market by Country, 2023 - 2030, USD Million
TABLE 37 US Specialty Generics Market, 2019 - 2022, USD Million
TABLE 38 US Specialty Generics Market, 2023 - 2030, USD Million
TABLE 39 US Specialty Generics Market by Type, 2019 - 2022, USD Million
TABLE 40 US Specialty Generics Market by Type, 2023 - 2030, USD Million
TABLE 41 US Specialty Generics Market by Application, 2019 - 2022, USD Million
TABLE 42 US Specialty Generics Market by Application, 2023 - 2030, USD Million
TABLE 43 US Specialty Generics Market by End Use, 2019 - 2022, USD Million
TABLE 44 US Specialty Generics Market by End Use, 2023 - 2030, USD Million
TABLE 45 Canada Specialty Generics Market, 2019 - 2022, USD Million
TABLE 46 Canada Specialty Generics Market, 2023 - 2030, USD Million
TABLE 47 Canada Specialty Generics Market by Type, 2019 - 2022, USD Million
TABLE 48 Canada Specialty Generics Market by Type, 2023 - 2030, USD Million
TABLE 49 Canada Specialty Generics Market by Application, 2019 - 2022, USD Million
TABLE 50 Canada Specialty Generics Market by Application, 2023 - 2030, USD Million
TABLE 51 Canada Specialty Generics Market by End Use, 2019 - 2022, USD Million
TABLE 52 Canada Specialty Generics Market by End Use, 2023 - 2030, USD Million
TABLE 53 Mexico Specialty Generics Market, 2019 - 2022, USD Million
TABLE 54 Mexico Specialty Generics Market, 2023 - 2030, USD Million
TABLE 55 Mexico Specialty Generics Market by Type, 2019 - 2022, USD Million
TABLE 56 Mexico Specialty Generics Market by Type, 2023 - 2030, USD Million
TABLE 57 Mexico Specialty Generics Market by Application, 2019 - 2022, USD Million
TABLE 58 Mexico Specialty Generics Market by Application, 2023 - 2030, USD Million
TABLE 59 Mexico Specialty Generics Market by End Use, 2019 - 2022, USD Million
TABLE 60 Mexico Specialty Generics Market by End Use, 2023 - 2030, USD Million
TABLE 61 Rest of North America Specialty Generics Market, 2019 - 2022, USD Million
TABLE 62 Rest of North America Specialty Generics Market, 2023 - 2030, USD Million
TABLE 63 Rest of North America Specialty Generics Market by Type, 2019 - 2022, USD Million
TABLE 64 Rest of North America Specialty Generics Market by Type, 2023 - 2030, USD Million
TABLE 65 Rest of North America Specialty Generics Market by Application, 2019 - 2022, USD Million
TABLE 66 Rest of North America Specialty Generics Market by Application, 2023 - 2030, USD Million
TABLE 67 Rest of North America Specialty Generics Market by End Use, 2019 - 2022, USD Million
TABLE 68 Rest of North America Specialty Generics Market by End Use, 2023 - 2030, USD Million
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Novartis AG
TABLE 71 Key Information – Hikma Pharmaceuticals PLC
TABLE 72 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 73 key information – Fresenius SE & Co. KGaA
TABLE 74 key information – Dr. Reddy’s Laboratories Ltd.
TABLE 75 Key information – Mallinckrodt PLC
TABLE 76 key information – Bausch Health Companies, Inc.
TABLE 77 key information – Viatris, Inc.
TABLE 78 Key Information – Apotex, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Product Launches and Product Expansions: 2020, May – 2023, Jan) Leading Players
FIG 5 North America Specialty Generics Market Share by Type, 2022
FIG 6 North America Specialty Generics Market Share by Type, 2030
FIG 7 North America Specialty Generics Market by Type, 2019 - 2030, USD Million
FIG 8 North America Specialty Generics Market share by Application, 2022
FIG 9 North America Specialty Generics Market share by Application, 2030
FIG 10 North America Specialty Generics Market by Application, 2019 - 2030, USD Million
FIG 11 North America Specialty Generics Market share by End Use, 2022
FIG 12 North America Specialty Generics Market share by End Use, 2030
FIG 13 North America Specialty Generics Market by End Use, 2019 - 2030, USD Million
FIG 14 North America Specialty Generics Market share by Country, 2022
FIG 15 North America Specialty Generics Market share by Country, 2030
FIG 16 North America Specialty Generics Market by Country, 2019 - 2030, USD Million
FIG 17 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 18 Recent strategies and developments: Novartis AG
FIG 19 Recent strategies and developments: Hikma Pharmaceuticals PLC
FIG 20 Recent strategies and developments: Sun Pharmaceutical Industries Ltd.